Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2000, for Schering-Plough Corporation (Note: The input metadata referenced Merck & Co., but the filing text explicitly identifies Schering-Plough Corporation). The company operates in pharmaceuticals, animal health, and consumer health products. As of June 30, 2000, there were 1,464,932,783 common shares outstanding.
Key Financial Metrics
| Metric | Q2 2000 | Q2 1999 | YTD 2000 | YTD 1999 |
|---|---|---|---|---|
| Net Sales | $2,642 million | $2,451 million | $5,048 million | $4,637 million |
| Net Income | $634 million | $547 million | $1,262 million | $1,086 million |
| Diluted EPS | $0.43 | $0.37 | $0.85 | $0.73 |
| Operating Cash Flow (YTD) | $1,096 million (vs. $767 million YTD 1999) | |||
| Cash and Equivalents | $2,039 million (as of June 30, 2000) | |||
| Short-term Borrowings | $857 million (as of June 30, 2000) | |||
| Long-term Liabilities | $964 million (as of June 30, 2000) |
Margins: Cost of sales decreased to 18.5% of sales in Q2 2000 (from 19.3% in Q2 1999). Income before taxes represented 31.6% of sales in Q2 2000 (up from 29.6% in Q2 1999). The effective tax rate was 24.0% for the period.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% in Q2 and 9% year-to-date (YTD) compared to 1999. Excluding foreign currency impacts, sales grew 10% in Q2 and 11% YTD.
- Profitability: Net income rose 16% in both Q2 and YTD periods. Diluted EPS increased 16% to $0.43 in Q2 and $0.85 YTD.
- Product Performance:
- Allergy & Respiratory: Sales up 8% (Q2) and 9% (YTD), driven by CLARITIN (up 9% Q2) and NASONEX (up 32% Q2).
- Anti-infective & Anticancer: Sales surged 25% (Q2) and 21% (YTD), led by INTRON A/REBETRON combination therapy and new launches of TEMODAR and REMICADE.
- Declines: Cardiovascular sales dipped 2% in Q2 due to generic competition for IMDUR. OTC sales fell 12% YTD due to the prior year sale of the PAAS product line.
- Acquisition: On June 25, 2000, the company acquired a majority interest in a joint venture with Takeda Chemical Industries for animal health products in Japan for approximately $48 million.
Guidance, Outlook, and Risks
Guidance: Management stated that earnings per share for the full year 2000 are expected to be in line with the current consensus of analysts' estimates of $1.64.
Capital Allocation:
- Share Repurchases: $445 million used in the first six months. A $1.5 billion repurchase program authorized in March 2000 was approximately 6% complete as of June 30.
- Dividends: Quarterly dividend increased 12% to $0.14 per share in April 2000. Total dividends paid YTD were $390 million.
- Capital Expenditures: $252 million spent YTD; full-year 2000 capex is expected to exceed $750 million.
Risks and Contingencies:
- Patent Litigation: Significant ongoing litigation regarding CLARITIN patents (challenges by Geneva, Copley, Teva, Andrx, Mylan, and American Home Products) and PEG-INTRON (lawsuit by Hoffman-La Roche). Outcomes are uncertain and could impact future sales.
- Antitrust Investigations: Ongoing FTC investigation into prescription drug pricing and a U.S. Attorney's Office inquiry into disease management marketing practices and rebate calculations.
- Regulatory Issues: FDA Warning Letters regarding manufacturing issues at New Jersey facilities (aerosol products). The company is implementing remedial actions, but future regulatory action or product recalls remain a risk.
- Environmental/Legal: Ongoing Superfund cleanup obligations and various antitrust class actions, though management believes accrued liabilities are sufficient and outcomes are not expected to be material beyond current accruals.
Investor Verification Checklist
- Verify the status of the CLARITIN patent litigation and potential impact on the company's largest revenue driver.
- Monitor the outcome of the FTC and U.S. Attorney's Office investigations regarding pricing and marketing practices.
- Assess the resolution of FDA manufacturing concerns at the New Jersey facilities and any potential for future product recalls.
- Track the progress of the $1.5 billion share repurchase program and its impact on earnings per share.
- Confirm the trajectory of foreign currency exchange rates, which are currently negatively impacting reported sales growth.